<DOC>
	<DOCNO>NCT02228655</DOCNO>
	<brief_summary>FMX-8 new type drug test treatment anemia chronic illness .</brief_summary>
	<brief_title>An Exploratory Study Evaluate FMX-8 Treat Anemia CKD</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>document hemoglobin level less 10 g/dL screening diagnose CKD 4 5 body mass index ( BMI ) 18 kg/m2 42 kg/m2 , inclusive , base upon height weight screen ferritin level ≥100 ng/ml Tsat ≥20 % screen erythropoietin ( EPO ) level great 8 ng/mL able provide write informed consent able understand follow trial procedure willing use contraception detail protocol receipt red blood cell ( RBC ) transfusion within four week screen overt gastrointestinal bleeding bleed episode require transfusion within 2 month prior screen infection necessitate antibiotic antiviral treatment within month prior screen require Coumadin ( warfarin ) , Pradaxa® , Eliquis® , Xarelto® hemoglobinopathies homozygous sicklecell disease thalassemia type active hemolysis chronic hypoxia active malignant disease ( except nonmelanoma skin cancer ) life expectancy le 6 month chronic , uncontrolled symptomatic inflammatory disease nonrenal cause anemia rheumatoid arthritis , systemic lupus erythematosus , HIV , systemic acute infection immunosuppressive therapeutic except topical corticosteroid nasal spray chronic congestive heart failure ( New York Heart Association Class III , IV ) significant hypertension ( ≥90 diastolic ) base sit diastolic blood pressure screen kidney transplant within past year : patient immunosuppressive agent follow fail transplant eligible trial endstage liver disease know hypersensitivity recombinant protein therapy female patient pregnant breast feed previous exposure FMX8 previous exposure Epogen® , Procrit® ( erythropoietin ) Aranesp® ( darbepoietin alpha ) , Omontys® Hematide® ( peginesatide ) anemia treatment uncontrolled hyperparathyroidism ( PTH &gt; 750 ) base upon late PTH determination within past 4 month inability comply trial schedule visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>CKD</keyword>
	<keyword>Anemia Chronic Illness</keyword>
</DOC>